On August 2, 2021, Abbott announced the FreeStyle Libre 2 iOS app received approval from the U.S. Food and Drug Administration (FDA) for adults and children ages 4 and up with diabetes. This app is used with the Abbott FreeStyle Libre 2 Continuous Glucose Monitoring (CGM) system, which was approved on June 15, 2020.
Prior to this approval, FreeStyle Libre 2 users had to wave a reader over the glucose sensor. Now, they can use their iPhone instead of a reader. Once scanned, the minute-by-minute data integrates with the existing LibreLinkUp app, allowing others to view blood-glucose levels in real-time.
“This is good news for the type 1 diabetes community, as it gives people with type 1 diabetes another convenient way to monitor their blood-glucose levels and share them with caregivers and healthcare providers,” said Jonathan Rosen, Ph.D., JDRF Associate Director, Research. “There is a considerable mental burden that comes with type 1 diabetes, and JDRF applauds the FDA for approving an app that has the potential to lessen that burden.”
JDRF has long supported CGM technology, funding research to develop these revolutionary devices and working tirelessly to ensure they are available to the T1D community. JDRF funded the landmark study that showed CGM use improves outcomes for people with T1D, which led to payer coverage of CGMs, and advocates tirelessly for coverage of these devices by commercial insurers and government programs such as Medicare. JDRF is committed to better, smaller, less intrusive devices that allow people with T1D to do better until there are cures. You can learn more about these efforts along with the rest of our Improving Lives portfolio here.
There is no date for when the app will appear in the App Store to download, but Abbott has stated it will be available soon.
Learn more at via the Abbott Press Release.